(Total Views: 325)
Posted On: 07/27/2018 9:41:45 AM
Post# of 72446
As I've said before, I think your numbers are way way way too high (like 5-10x). To my knowledge there has never been a pre-phase 3 deal worth close to a "minimum of $50B."
If we match Otezla I think $3B-$5B would be the buyout range for the company. That's why I think IPIX would prefer partnerships with an acquisition later on for more money. Big pharma is risk averse. They'd rather make 2x their money on a sure thing rather than swing for the fences.
If we match Otezla I think $3B-$5B would be the buyout range for the company. That's why I think IPIX would prefer partnerships with an acquisition later on for more money. Big pharma is risk averse. They'd rather make 2x their money on a sure thing rather than swing for the fences.
(2)
(2)
